Iterum Therapeutics Plc (ITRM) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
- Shipping stocks on fire — but cracks are forming in the rate rally
Iterum Therapeutics Reports Second Quarter 2022 Financial Results
August 12, 2022 7:00 AM EDT--Enrollment in Registration Trial for uUTI to Begin Q4 2022--
--Cash Runway into 2024-- Â Â
DUBLIN, Ireland and CHICAGO, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the second quarter ended June 30, 2022.
We are excited to start our planned Phase 3 clinical trial in uncomplicated urinary tract infections (uUTI)... More
